Merck appoints UK leadership team
pharmafile | January 26, 2010 | Appointment | | MSD, Merck & Co, appointment
Merck & Co’s UK business has unveiled its new leadership team, following last year’s merger with Schering-Plough.
Merck Sharp & Dohme’s Human Health Leadership Team appointments are:
Haseeb Ahmad – director of strategy
Keith Bousfield – director of primary care marketing
David Hewitt – director of consumer health
Jim Page – immunology business unit director
Kevin Peters – director of business operations
Chris Ponty – specialty business unit director
Kate Tillett – director of external affairs
Sally-Anne Tsangarides – hospital business unit director
Ilse van Roy – women’s health business unit director
Craig Wallace – primary care sales director
Tim Williams – director of market access
UK managing director Deepak Khanna said: “The outline shape for our organisation in the UK combines the strengths of both legacy companies.
“At the heart of our organisation is our aspiration to be viewed by the NHS as their most trusted and valued healthcare partner, and to make a substantial difference to patients.”
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

Merck shares data from phase 3 trial of Keytruda for gastric cancers
Merck, known as MSD outside of the US and Canada, has announced data from the …






